OncoMatch/Clinical Trials/NCT06926075
Early Phase Study of KESONOTIDE™in Participants With Solid Tumours
Is NCT06926075 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including A novel hGIIA-Vimentin Inhibitor and Dose expansion for prostate cancers.
Treatment: A novel hGIIA-Vimentin Inhibitor · Dose expansion — This clinical trial is an adaptive study of a novel vimentin inhibitor in cancers. It is an open label, multicentre, single ascending dose level in phase I and cohort exploration in phase II. Primary objective is to evaluate safety and tolerability of KESONOTIDE™ as a monotherapy in participants with advanced/metastatic solid cancers. Secondary objective is to characterise the pharmacokinetics of KESONOTIDE™. Phase I study will enrol 20-32 participants and Phase II approximately 80 participants.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Ovarian Cancer
Glioblastoma
Pancreatic Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Lab requirements
Blood counts
Platelet count > 100 x 10^9/L; Hb > 9.0 g/dL; ANC > 1.5 x 10^9/L
Kidney function
Creatinine < 1.5 x ULN
Liver function
AST and ALT < 3 x ULN for the reference laboratory or < 5 x ULN in the presence of liver metastases; total bilirubin ≤ 1.5 x ULN; serum albumin ≥ 2.5 g/dL
Has adequate organ function within 7 days prior to Day 1 of Cycle 1, defined as below: Platelet count > 100 x 10^9/L; Hb > 9.0 g/dL; ANC > 1.5 x 10^9/L; Creatinine < 1.5 x ULN; AST and ALT < 3 x ULN for the reference laboratory or < 5 x ULN in the presence of liver metastases; Total bilirubin ≤ 1.5 x ULN; Serum albumin ≥ 2.5 g/dL; INR/PT and APTT ≤ 1.5 x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify